Molindone — Membership Pricing

Other medications in Mental Health

• Naltrexone
• Nefazodone
• Nortriptyline
• Olanzapine
• Paliperidone
• Paroxetine
• Perphenazine
• Phenelzine

About Molindone

Molindone is an antipsychotic medication primarily used to manage the symptoms of schizophrenia. Understanding its role in treatment and potential costs is crucial. At TheDrugClub, we believe in making essential medications like molindone more accessible and affordable, helping our members navigate prescription expenses with confidence and significant savings.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Molindone is approved for (FDA label)

Molindone Hydrochloride Tablets, USP are indicated for the management of schizophrenia. The efficacy of Molindone Hydrochloride Tablets, USP in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects.

Source: Read the full FDA label on DailyMed. Label effective date: December 17, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Molindone (FDA label)

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis – Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Molindone Hydrochloride Tablets, USP are not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 1275e92f-9573-4d0c-8e77-1c9ac47696d2. SPL document ID: d7c8ea49-c06c-441d-820e-def3920f7c1e. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Molindone (FDA label)

CNS Effects The most frequently occurring effect is initial drowsiness that generally subsides with continued usage of the drug or lowering of the dose. Noted less frequently were depression, hyperactivity and euphoria. Neurological Extrapyramidal Symptoms Extrapyramidal symptoms noted below may occur in susceptible individuals and are usually reversible with appropriate management. Akathisia Motor restlessness may occur early. Parkinson Syndrome Akinesia, characterized by rigidity, immobility and reduction of voluntary movements and tremor, have been observed. Occurrence is less frequent than akathisia. Dystonia Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.

Source: FDA prescribing information (DailyMed). Set ID: 1275e92f-9573-4d0c-8e77-1c9ac47696d2. SPL document ID: d7c8ea49-c06c-441d-820e-def3920f7c1e. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Molindone (FDA label)

Molindone Hydrochloride Tablets are contraindicated in severe central nervous system depression (alcohol, barbiturates, narcotics, etc.) or comatose states, and in patients with known hypersensitivity to the drug.

Source: FDA prescribing information (DailyMed). Set ID: 1275e92f-9573-4d0c-8e77-1c9ac47696d2. SPL document ID: d7c8ea49-c06c-441d-820e-def3920f7c1e. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Molindone (FDA label)

Potentiation of drugs administered concurrently with Molindone Hydrochloride has not been reported. Additionally, animal studies have not shown increased toxicity when Molindone Hydrochloride is given concurrently with representative members of three classes of drugs (i.e., barbiturates, chloral hydrate and antiparkinson drugs).

Source: FDA prescribing information (DailyMed). Set ID: 1275e92f-9573-4d0c-8e77-1c9ac47696d2. SPL document ID: d7c8ea49-c06c-441d-820e-def3920f7c1e. Label effective date: December 17, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.